Mitsubishi Chemical Corporation: Patent Pertinent to Lithium-ion Secondary Battery for Vehicles Granted
2.2.2021 07:00:00 EET | Business Wire | Press release
Mitsubishi Chemical Corporation (“MCC”; HQ: Chiyoda-ku, Tokyo, President and Representative Director: Masayuki Waga) and MU Ionic Solutions Corporation (“MUIS”; HQ: Chiyoda-ku, Tokyo, President and Representative Director: Masaaki Tsuchiyama) announce the grant by the European Patent Office (“EPO”) of their jointly owned European patent pertaining to a lithium-ion secondary battery (European Patent Application Number: 06 83 2384.9; “the Patent”). The Patent, which relates to a lithium-ion secondary battery for vehicles, covers a combination of a nickel-containing positive electrode material, which is the standard choice in lithium-ion secondary batteries for vehicles, and an electrolyte comprising lithium difluorophosphate. The Patent, which has already been granted in Japan, US, China as well as South Korea, has now been additionally granted by the EPO with effect in Germany, where the demand for electric vehicles is increasing.
In recent years, nickel-containing positive electrode materials have been used in vehicle batteries because of their greater energy storage per unit volume when compared with other materials, and in order to achieve a higher capacity battery. The Patent offers a technology with extraordinary advantages for building batteries with a long life and high output, and in particular for a battery which is suited for quick recharging. This is a highly awaited development in terms of vehicle use, since this new technology, incorporating difluorophosphoric acid salt as the active component, is capable of improving the output characteristics of the batteries, in particular over known batteries using nickel-containing positive electrode materials, as well as the long-term retention of capacity, even after repeated charge/discharge cycles.
MCC and MUIS hold, apart from the Patent, a large number of further patents relating to materials for lithium-ion secondary batteries for vehicles. The prevalence of electric automobiles is expected to increase in the coming years across the globe, especially in Europe: this is driven not only as a solution to environmental challenges, such as the reduction of fossil fuel consumption and harmful gas emission, but also to allow a new society of next-generation mobility to be realized. MCC and MUIS will vigorously continue, in response to voracious demand, our activities as leading companies in the field of electrolytes for lithium-ion secondary batteries for vehicles, while promoting the healthy expansion of this market by means of appropriate use of intellectual property rights, thereby contributing to the realisation of a sustainable, next-generation society.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005012/en/
Contact information
For further information, please contact:
Public Relations and Investor Relations Office
Mitsubishi Chemical Holdings Corporation
Norihiko Urabe
Tel: [+81] (0)3-6748-7140
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance29.4.2026 15:06:00 EEST | Press release
Tecnotree, a global digital platform and services provider for AI-enabled 5G and cloud-native technologies, today announced its financial results for the first quarter of 2026, demonstrating stable revenue, strong profitability, and a robust order backlog despite geopolitical uncertainties across global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429319948/en/ Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance Key Financial Highlights – Q1 2026 Revenue of EUR 16.8 million (16.9), revenue in constant currency EUR 17.1 million, +1.0% YoY. EBIT of EUR 4.6 million (4.5), +1.8% YoY. EBIT margin of 27.4% (26.9%), +50 basis points YoY. Foreign exchange (FX) gains EUR 1.0 million (-1.4). Net income EUR 2.1 million (1.5), +36.5% YoY. Free cash flow (FCF) EUR 0.2 million (1.0). Earnings per share (EPS) EUR 0.1 (0.1). Order book at the end of the period EUR 105.4 million
SS&C Unveils WorkHQ to Power Enterprise Agentic Automation29.4.2026 15:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the launch of SS&C Blue Prism WorkHQ, its agentic automation platform designed to help enterprises operationalize agentic AI safely, transparently and with full control of end-to-end workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429512507/en/ Unveiled at a live event at Nasdaq in New York City, WorkHQ introduces a unified control plane orchestrating people, AI agents, APIs and digital workers into a single governed environment. SS&C developed WorkHQ based on its own experience operating at scale across regulated industries. Today, SS&C supports more than 23,000 customers globally with the help of 4,000+ digital workers and more than 50 AI agents. These efforts have enabled SS&C to significantly improve operational efficiency in key processes, reducing processing times by up to 95% in key workflows. “WorkHQ was built for the enterprise problem, not
Ecolab Life Sciences Expands Global Bioprocessing Capabilities With New Advanced Development and Applications Center in Korea29.4.2026 15:00:00 EEST | Press release
Building on the continued growth and strong performance of its Life Sciences business, Ecolab is further expanding its global bioprocessing capabilities to support biopharmaceutical manufacturers worldwide. Today, Ecolab Life Sciences announced the opening of a new Bioprocessing Applications Lab (BPAL) in Dongtan, Korea, its first bioprocessing facility in Asia. The new center further strengthens the company’s global Life Sciences footprint and supports customers operating in one of the world’s most advanced biopharmaceutical manufacturing markets. The Korea BPAL supports a full range of process development activities from early-stage testing through studies that replicate manufacturing at scale, building on Ecolab’s established bioprocessing applications network in the United States and the United Kingdom. The facility enables hands-on collaboration with Ecolab’s bioprocessing experts to help customers optimize purification processes, enhance cost and process efficiency, and advance p
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 14:42:00 EEST | Press release
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429263104/en/ • Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 14:00:00 EEST | Press release
Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S. Marines. The Next Generation EW prototype is centered on the C5ISR Modular Open Suite of S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
